Discontinuation was common: 54.2% of the patients in the study data discontinued their GLP-1 RA (30 days without medication on hand), highlighting the need for additional research on the role of shortages, adverse events, and costs
Anbazhagan AN, Thaqi M, Priyamvada S, Jayawardena D, Kumar A, Gujral T, et al
Its important to note that these peptides are not FDA-approved drugs
The heterogeneity of mutations that lead to RP has led to a variety of approaches that attempt to address larger portions of the patient population
However, the focus is generally on how the nasal delivery devices could achieve the maximum dose deposition in the upper part of the nose cavity, thus targeting the brain
Cloudiness, particles, clumping, aggregation, or precipitation may be caused by peptide/diluent incompatibility